共 50 条
- [31] Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple MyelomaClinical Hematology International, 2023, 5 (1) : 43 - 51Plesner T.Harrison S.J.Quach H.Lee C.Bryant A.Vangsted A.Estell J.Delforge M.Offner F.Twomey P.Choeurng V.Li J.Hendricks R.Ruppert S.M.Sumiyoshi T.Miller K.Cho E.Schjesvold F.
- [32] A BCL2L1 armoured BCMA-targeting CAR T cells to overcome exhaustion and enhance persistence in multiple myelomaCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S12 - S12Maity, RanjanBenaoudia, SachaLee, HollyBarakat, ElieLeblay, NoemieAhn, SungwooZemp, FranzMahoney, DouglasNeri, PaolaBahlis, Nizar
- [33] Efficacy and Safety of ABBV-383, a BCMA Bispecific Antibody, in Black Patients With Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis of a Phase 1 TrialCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S48 - S48D'Souza, AnitaRodriguez-Valdes, CesarKumar, ShajiChung, AlfredTuchman, SaschaSafah, HanaWeisel, KatjaTeipel, RaphaelKorde, NehaVij, RaviBueno, OrlandoRosenberg, TanyaPothacamury, RajvineethPolepally, AkshanthAhsan, AarifLee, ShaneJin, ZiyiSpence, ShelliTalati, ChetasiMcKay, JohnVoorhees, Peter M.
- [34] Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1BLOOD, 2022, 140Cortes-Selva, DianaCasneuf, TinekeVishwamitra, DeekshaStein, SarahPerova, TatianaSkerget, SheriRamos, Elenavan Steenbergen, LaureDe Maeyer, DriesBoominathan, RengasamyLau, OnsayDavis, CucBanerjee, ArnobStephenson, TaraUhlar, Clarissa M.Kobos, RachelGoldberg, Jenna D.Pei, LixiaTrancucci, DanielleGirgis, SuzetteLin, Shun Xin WangWu, Liviawati S.Moreau, PhilippeUsmani, SaadBahlis, Nizar JacquesVan de Donk, Niels W. C. J.Verona, Raluca
- [35] Long-Term Follow-up of Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple MyelomaBLOOD, 2023, 142Li, ChunruiDi WangYu, QiuxiaLi, ZheWang, WenHu, GuangMu, WeiLi, ChunhuiAn, NingLong, XiaoluBao, Yuhan
- [36] Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Valdes, Cesar RodriguezVoorhees, Peter M.D'Souza, AnitaChung, AlfredTuchman, SaschaSafah, HanaMckay, John T.Weisel, Katja C.Teipel, RaphaelKorde, NehaVij, RaviBueno, Orlando FelixRosenberg, TanyaPothacamury, Rajvineeth KumarPolepally, AkshanthAhsan, AarifLi , XinJin, ZiyiTalati, ChetasiKumar, Shaji
- [37] Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results (vol 29, 422, 2023)NATURE MEDICINE, 2023, 29 (12) : 3271 - 3271Mailankody, ShamMatous, Jeffrey V.Chhabra, SaurabhLiedtke, MichaelaSidana, SurbhiOluwole, Olalekan O.Malik, ShahbazNath, RajneeshAnwer, FaizCruz, Jose CarlosHtut, MyoKarski, Erin E.Lovelace, WadeDillon, MylesButz, EricYing, WendyBalakumaran, ArunKumar, Shaji K.
- [38] A Phase I Study of RO7297089, a B-Cell Maturation Antigen (BCMA)-CD16a Bispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)BLOOD, 2021, 138Plesner, TorbenHarrison, Simon J.Quach, HangLee, Cindy H.Bryant, AdamVangsted, Annette JuulEstell, JaneDelforge, MichelOffner, FritzTwomey, PatrickChoeurng, VoleakLi, JunyiHendricks, RobertSumiyoshi, TeikoMiller, KarenChoi, EunpiSchjesvold, Fredrik H.
- [39] Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Touzeau, CyrilleKrishnan, Amrita Y.Moreau, PhilippePerrot, AuroreUsmani, Saad ZafarManier, SalomonCavo, MicheleMartinez-Chamorro, CarmenNooka, Ajay K.Martin, Thomas G.Karlin, LionelLeleu, XavierBahlis, Nizar J.Besemer, BrittaPei, LixiaVerona, RalucaGirgis, SuzetteUhlar, ClarissaKobos, RachelGarfall, Alfred L.
- [40] A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody).JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Rodriguez-Otero, PaulaD'Souza, AnitaReece, Donna Ellenvan de Donk, Niels W. C. J.Chari, AjaiKrishnan, Amrita Y.Martin, Thomas G.Mateos, Maria-VictoriaMorillo, DanielHurd, David DuaneRosinol, LauraBalari, Anna SuredaWasch, RalphVishwamitra, DeekshaLin, Shun Xin WangPrior, ThomasVandenberk, LienSmit, Marie-Anne DamietteRocafiguera, Albert OriolDholaria, Bhagirathbhai R.